Zymeworks Inc. cotiza a 25.33 USD y tiene una capitalización bursátil de $1.8B. En los últimos 12 meses ha facturado $37M con un margen de flujo de caja libre del -32.6%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubul…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-0.62 | $-0.59 | $-0.55 |
| Estimado | $2.15 | $-0.58 | $-0.10 | $-0.32 |
| Sorpresa | — | -6.9% | -490.0% | -71.9% |
| Métrica | ZYME | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -87.3% | -38.6% | -48.7% |
| Net Margin | -76.6% | -33.6% | -43.0% |
| FCF Margin | -32.6% | -13.9% | -18.7% |
| ROE | -30.2% | -40.4% | +10.2% |
| ROA | -23.4% | -32.0% | +8.6% |
| Current Ratio | 5.88 | 2.84 | +3.04 |
| Debt / Equity | — | 0.28 | — |